Compare Repligen Corporation Common Stock (RGEN) vs RingCentral Inc. Class A Common Stock (RNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs RingCentral Inc. Class A Common Stock — how do they compare? Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B), while RingCentral Inc. Class A Common Stock trades at $75.4 (market cap $6.53B). The key difference: Repligen Corporation Common Stock is the larger of the two by market cap, and RingCentral Inc. Class A Common Stock pays a 0.35% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and RingCentral Inc. Class A Common Stock for 6 Days on average.
| RGEN | RNG | |
|---|---|---|
Market Cap | $11.14B | $6.53B |
Volume | 1,259,263 | 1,430,504 |
Sector | Health | Technology |
52-Week High | $194.57 | $79.82 |
52-Week Low | $102.87 | $24.82 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $11.02B | $7.58B |
Dividend Yield | — | 0.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
RingCentral (RNG) trades at $78.69, up 0.67% on the day and near its 52-week high, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend. Fundamentally, the company shows revenue growth to $2.52 billion in 2025, with net income of $43.39 million and improving margins. Recent earnings beats and strategic AI partnerships, like the one with Allnet.Italia announced October 13, 2026, underscore growth potential. Analyst sentiment is overwhelmingly positive with 28 buy ratings and a consensus price target of $61.00, though the current price exceeds this target.
The outlook for RNG is favorable driven by AI integration and earnings momentum, but risks include high valuation with a P/E of 62.54 and potential volatility ahead of Q3 2026 results on October 22, 2026. Investor focus remains on execution and margin expansion amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About RingCentral Inc. Class A Common Stock
RingCentral provides cloud-based business communications and contact center solutions. Its platform combines phone, messaging, video meetings, and customer-service tools.
Read more on RNG →
